Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

Apostolia M. Tsimberidou, Susan M. O'Brien, Jorge E. Cortes, Stefan Faderl, Michael Andreeff, Hagop M. Kantarjian, Michael J. Keating, Francis J. Giles

Research output: Contribution to journalArticle

Abstract

A phase II study was conducted to evaluate the safety and efficacy of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment in patients with Richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin's lymphoma (NHL). Twenty-two patients with RS, refractory PLL, or refractory NHL were entered into this trial between March 1997 and February 2001. Median age was 62 years (42-74); 77% were over 60 years of age. Histologic diagnosis was large cell NHL transformation in 15 patients with CLL, immunoblastic transformation of CLL in one, refractory PLL in three, and refractory NHL in three patients. Treatment consisted of fludarabine 30 mg/m2 (days 1-3), ara-C 0.5 g/m2 (days 3-4), cyclophosphamide 250 mg/m2 (days 2-4), cisplatin 15 mg/m2 IV CI (days 1-4) with GM-CSF 250 μg/m2 from day 5 to recovery of neutrophils and antibiotic prophylaxis. Patients with response were to receive a maximum of six cycles of therapy. Eighteen patients were evaluable for response; one patient achieved a complete remission (5%), 12 stable disease/no response (67%) and five patients had progressive disease (28%). The median survival was 2.2 months (range, 1-19); the median failure-free survival was 1.5 months (range, 0.5-18.6). Grade III/IV toxicities were as follows: anemia in 62% of cycles; leucopoenia in 66%; granulocytopenia in 90%; thrombocytopenia in 83%; hyperbilirubinemia in 14%; hyperuricemia in 17%; hyponatremia in 17%; hypokalemia in 14%; hypophosphatemia in 10%; hypoalbulinemia in 14%; hypocalcemia in 7%; and hypercalcemia in 3%. One (3%) patient developed cardiac failure. Forty-one percent of the cycles were complicated with fever, 34% with non-neutropenic fever, and 55% cycles with infections (fungal 31%; bacterial 57%; HSV 6%; VZV 6%). FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders.

Original languageEnglish (US)
Pages (from-to)767-772
Number of pages6
JournalLeukemia and Lymphoma
Volume43
Issue number4
DOIs
StatePublished - May 4 2002
Externally publishedYes

Fingerprint

Lymphoproliferative Disorders
Cytarabine
Granulocyte-Macrophage Colony-Stimulating Factor
Cyclophosphamide
Cisplatin
Prolymphocytic Leukemia
Non-Hodgkin's Lymphoma
Fever
fludarabine
Hypophosphatemia
Hyperuricemia
Agranulocytosis
Hyperbilirubinemia
Survival
Hypokalemia
Antibiotic Prophylaxis
Hypocalcemia
Mycoses
Hyponatremia
Hypercalcemia

Keywords

  • Fludarabine-containing regimens
  • LPD
  • Refractory lymphoma
  • Richter's syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. / Tsimberidou, Apostolia M.; O'Brien, Susan M.; Cortes, Jorge E.; Faderl, Stefan; Andreeff, Michael; Kantarjian, Hagop M.; Keating, Michael J.; Giles, Francis J.

In: Leukemia and Lymphoma, Vol. 43, No. 4, 04.05.2002, p. 767-772.

Research output: Contribution to journalArticle

Tsimberidou, Apostolia M. ; O'Brien, Susan M. ; Cortes, Jorge E. ; Faderl, Stefan ; Andreeff, Michael ; Kantarjian, Hagop M. ; Keating, Michael J. ; Giles, Francis J. / Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. In: Leukemia and Lymphoma. 2002 ; Vol. 43, No. 4. pp. 767-772.
@article{a3aeffd721384cf6ad09dbfe4f5fc5b9,
title = "Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders",
abstract = "A phase II study was conducted to evaluate the safety and efficacy of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment in patients with Richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin's lymphoma (NHL). Twenty-two patients with RS, refractory PLL, or refractory NHL were entered into this trial between March 1997 and February 2001. Median age was 62 years (42-74); 77{\%} were over 60 years of age. Histologic diagnosis was large cell NHL transformation in 15 patients with CLL, immunoblastic transformation of CLL in one, refractory PLL in three, and refractory NHL in three patients. Treatment consisted of fludarabine 30 mg/m2 (days 1-3), ara-C 0.5 g/m2 (days 3-4), cyclophosphamide 250 mg/m2 (days 2-4), cisplatin 15 mg/m2 IV CI (days 1-4) with GM-CSF 250 μg/m2 from day 5 to recovery of neutrophils and antibiotic prophylaxis. Patients with response were to receive a maximum of six cycles of therapy. Eighteen patients were evaluable for response; one patient achieved a complete remission (5{\%}), 12 stable disease/no response (67{\%}) and five patients had progressive disease (28{\%}). The median survival was 2.2 months (range, 1-19); the median failure-free survival was 1.5 months (range, 0.5-18.6). Grade III/IV toxicities were as follows: anemia in 62{\%} of cycles; leucopoenia in 66{\%}; granulocytopenia in 90{\%}; thrombocytopenia in 83{\%}; hyperbilirubinemia in 14{\%}; hyperuricemia in 17{\%}; hyponatremia in 17{\%}; hypokalemia in 14{\%}; hypophosphatemia in 10{\%}; hypoalbulinemia in 14{\%}; hypocalcemia in 7{\%}; and hypercalcemia in 3{\%}. One (3{\%}) patient developed cardiac failure. Forty-one percent of the cycles were complicated with fever, 34{\%} with non-neutropenic fever, and 55{\%} cycles with infections (fungal 31{\%}; bacterial 57{\%}; HSV 6{\%}; VZV 6{\%}). FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders.",
keywords = "Fludarabine-containing regimens, LPD, Refractory lymphoma, Richter's syndrome",
author = "Tsimberidou, {Apostolia M.} and O'Brien, {Susan M.} and Cortes, {Jorge E.} and Stefan Faderl and Michael Andreeff and Kantarjian, {Hagop M.} and Keating, {Michael J.} and Giles, {Francis J.}",
year = "2002",
month = "5",
day = "4",
doi = "10.1080/10428190290016872",
language = "English (US)",
volume = "43",
pages = "767--772",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Phase II study of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

AU - Tsimberidou, Apostolia M.

AU - O'Brien, Susan M.

AU - Cortes, Jorge E.

AU - Faderl, Stefan

AU - Andreeff, Michael

AU - Kantarjian, Hagop M.

AU - Keating, Michael J.

AU - Giles, Francis J.

PY - 2002/5/4

Y1 - 2002/5/4

N2 - A phase II study was conducted to evaluate the safety and efficacy of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment in patients with Richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin's lymphoma (NHL). Twenty-two patients with RS, refractory PLL, or refractory NHL were entered into this trial between March 1997 and February 2001. Median age was 62 years (42-74); 77% were over 60 years of age. Histologic diagnosis was large cell NHL transformation in 15 patients with CLL, immunoblastic transformation of CLL in one, refractory PLL in three, and refractory NHL in three patients. Treatment consisted of fludarabine 30 mg/m2 (days 1-3), ara-C 0.5 g/m2 (days 3-4), cyclophosphamide 250 mg/m2 (days 2-4), cisplatin 15 mg/m2 IV CI (days 1-4) with GM-CSF 250 μg/m2 from day 5 to recovery of neutrophils and antibiotic prophylaxis. Patients with response were to receive a maximum of six cycles of therapy. Eighteen patients were evaluable for response; one patient achieved a complete remission (5%), 12 stable disease/no response (67%) and five patients had progressive disease (28%). The median survival was 2.2 months (range, 1-19); the median failure-free survival was 1.5 months (range, 0.5-18.6). Grade III/IV toxicities were as follows: anemia in 62% of cycles; leucopoenia in 66%; granulocytopenia in 90%; thrombocytopenia in 83%; hyperbilirubinemia in 14%; hyperuricemia in 17%; hyponatremia in 17%; hypokalemia in 14%; hypophosphatemia in 10%; hypoalbulinemia in 14%; hypocalcemia in 7%; and hypercalcemia in 3%. One (3%) patient developed cardiac failure. Forty-one percent of the cycles were complicated with fever, 34% with non-neutropenic fever, and 55% cycles with infections (fungal 31%; bacterial 57%; HSV 6%; VZV 6%). FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders.

AB - A phase II study was conducted to evaluate the safety and efficacy of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment in patients with Richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin's lymphoma (NHL). Twenty-two patients with RS, refractory PLL, or refractory NHL were entered into this trial between March 1997 and February 2001. Median age was 62 years (42-74); 77% were over 60 years of age. Histologic diagnosis was large cell NHL transformation in 15 patients with CLL, immunoblastic transformation of CLL in one, refractory PLL in three, and refractory NHL in three patients. Treatment consisted of fludarabine 30 mg/m2 (days 1-3), ara-C 0.5 g/m2 (days 3-4), cyclophosphamide 250 mg/m2 (days 2-4), cisplatin 15 mg/m2 IV CI (days 1-4) with GM-CSF 250 μg/m2 from day 5 to recovery of neutrophils and antibiotic prophylaxis. Patients with response were to receive a maximum of six cycles of therapy. Eighteen patients were evaluable for response; one patient achieved a complete remission (5%), 12 stable disease/no response (67%) and five patients had progressive disease (28%). The median survival was 2.2 months (range, 1-19); the median failure-free survival was 1.5 months (range, 0.5-18.6). Grade III/IV toxicities were as follows: anemia in 62% of cycles; leucopoenia in 66%; granulocytopenia in 90%; thrombocytopenia in 83%; hyperbilirubinemia in 14%; hyperuricemia in 17%; hyponatremia in 17%; hypokalemia in 14%; hypophosphatemia in 10%; hypoalbulinemia in 14%; hypocalcemia in 7%; and hypercalcemia in 3%. One (3%) patient developed cardiac failure. Forty-one percent of the cycles were complicated with fever, 34% with non-neutropenic fever, and 55% cycles with infections (fungal 31%; bacterial 57%; HSV 6%; VZV 6%). FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders.

KW - Fludarabine-containing regimens

KW - LPD

KW - Refractory lymphoma

KW - Richter's syndrome

UR - http://www.scopus.com/inward/record.url?scp=0036239496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036239496&partnerID=8YFLogxK

U2 - 10.1080/10428190290016872

DO - 10.1080/10428190290016872

M3 - Article

C2 - 12153163

AN - SCOPUS:0036239496

VL - 43

SP - 767

EP - 772

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -